These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 25915848)
1. Paxillin confers resistance to tyrosine kinase inhibitors in EGFR-mutant lung cancers via modulating BIM and Mcl-1 protein stability. Wu DW; Chen CY; Chu CL; Lee H Oncogene; 2016 Feb; 35(5):621-30. PubMed ID: 25915848 [TBL] [Abstract][Full Text] [Related]
2. EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition. Nakagawa T; Takeuchi S; Yamada T; Ebi H; Sano T; Nanjo S; Ishikawa D; Sato M; Hasegawa Y; Sekido Y; Yano S Cancer Res; 2013 Apr; 73(8):2428-34. PubMed ID: 23382048 [TBL] [Abstract][Full Text] [Related]
3. PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation. Wu DW; Wu TC; Chen CY; Lee H Clin Cancer Res; 2016 Nov; 22(21):5370-5382. PubMed ID: 27178741 [TBL] [Abstract][Full Text] [Related]
4. An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling. Lin PL; Wu TC; Wu DW; Wang L; Chen CY; Lee H Eur J Cancer; 2017 Nov; 85():95-105. PubMed ID: 28892778 [TBL] [Abstract][Full Text] [Related]
5. TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells. Wu DW; Chen TC; Huang HS; Lee H Cell Death Dis; 2016 Jun; 7(6):e2290. PubMed ID: 27362807 [TBL] [Abstract][Full Text] [Related]
6. The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer. Zhao M; Zhang Y; Cai W; Li J; Zhou F; Cheng N; Ren R; Zhao C; Li X; Ren S; Zhou C; Hirsch FR Cancer; 2014 Aug; 120(15):2299-307. PubMed ID: 24737648 [TBL] [Abstract][Full Text] [Related]
7. Phosphorylation of paxillin confers cisplatin resistance in non-small cell lung cancer via activating ERK-mediated Bcl-2 expression. Wu DW; Wu TC; Wu JY; Cheng YW; Chen YC; Lee MC; Chen CY; Lee H Oncogene; 2014 Aug; 33(35):4385-95. PubMed ID: 24096476 [TBL] [Abstract][Full Text] [Related]
8. Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: sensitivity and resistance. Takeuchi S; Yano S Respir Investig; 2014 Nov; 52(6):348-56. PubMed ID: 25453378 [TBL] [Abstract][Full Text] [Related]
9. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. Costa DB; Halmos B; Kumar A; Schumer ST; Huberman MS; Boggon TJ; Tenen DG; Kobayashi S PLoS Med; 2007 Oct; 4(10):1669-79; discussion 1680. PubMed ID: 17973572 [TBL] [Abstract][Full Text] [Related]
10. BIM induction of apoptosis triggered by EGFR-sensitive and resistance cell lines of non-small-cell lung cancer. Li Z; Zhou S; Zhang L; Su C; Hang J; Zhao Y; Su B; Zhou C Med Oncol; 2011 Jun; 28(2):572-7. PubMed ID: 20237869 [TBL] [Abstract][Full Text] [Related]
12. MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer. Li B; Ren S; Li X; Wang Y; Garfield D; Zhou S; Chen X; Su C; Chen M; Kuang P; Gao G; He Y; Fan L; Fei K; Zhou C; Schmit-Bindert G Lung Cancer; 2014 Feb; 83(2):146-53. PubMed ID: 24331411 [TBL] [Abstract][Full Text] [Related]
13. Targeting Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer by Inducing Epidermal Growth Factor Receptor Degradation via Methionine 790 Oxidation. Leung EL; Fan XX; Wong MP; Jiang ZH; Liu ZQ; Yao XJ; Lu LL; Zhou YL; Yau LF; Tin VP; Liu L Antioxid Redox Signal; 2016 Feb; 24(5):263-79. PubMed ID: 26528827 [TBL] [Abstract][Full Text] [Related]
15. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Ng KP; Hillmer AM; Chuah CT; Juan WC; Ko TK; Teo AS; Ariyaratne PN; Takahashi N; Sawada K; Fei Y; Soh S; Lee WH; Huang JW; Allen JC; Woo XY; Nagarajan N; Kumar V; Thalamuthu A; Poh WT; Ang AL; Mya HT; How GF; Yang LY; Koh LP; Chowbay B; Chang CT; Nadarajan VS; Chng WJ; Than H; Lim LC; Goh YT; Zhang S; Poh D; Tan P; Seet JE; Ang MK; Chau NM; Ng QS; Tan DS; Soda M; Isobe K; Nöthen MM; Wong TY; Shahab A; Ruan X; Cacheux-Rataboul V; Sung WK; Tan EH; Yatabe Y; Mano H; Soo RA; Chin TM; Lim WT; Ruan Y; Ong ST Nat Med; 2012 Mar; 18(4):521-8. PubMed ID: 22426421 [TBL] [Abstract][Full Text] [Related]
16. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer. Donev IS; Wang W; Yamada T; Li Q; Takeuchi S; Matsumoto K; Yamori T; Nishioka Y; Sone S; Yano S Clin Cancer Res; 2011 Apr; 17(8):2260-9. PubMed ID: 21220474 [TBL] [Abstract][Full Text] [Related]
17. Gallic acid inhibition of Src-Stat3 signaling overcomes acquired resistance to EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer. Phan AN; Hua TN; Kim MK; Vo VT; Choi JW; Kim HW; Rho JK; Kim KW; Jeong Y Oncotarget; 2016 Aug; 7(34):54702-54713. PubMed ID: 27419630 [TBL] [Abstract][Full Text] [Related]
18. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235. Hall CP; Reynolds CP; Kang MH Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839 [TBL] [Abstract][Full Text] [Related]
19. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim. Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280 [TBL] [Abstract][Full Text] [Related]
20. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal. Li L; Han R; Xiao H; Lin C; Wang Y; Liu H; Li K; Chen H; Sun F; Yang Z; Jiang J; He Y Clin Cancer Res; 2014 May; 20(10):2714-26. PubMed ID: 24644001 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]